3D Cell Culture
3D Cell Culture
10th February to 11th February 2021,
Online Virtual Event , United Kingdom
SMi’s 5th Annual Conference
3D Cell Culture
February 10-11, 2021 | London, Copthorne Tara, United Kingdom
-------------------------------------------------------------------------
3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with the global 3D Cell Culture market predicted to reach a value of $3.2 Billion by 2027, researchers globally are realising the growing potential of in vitro applications for drug discovery, predictivity and validation, safety and toxicity.
Rising demand for tissue engineering for the treatment of chronic diseases is a key driver of this research and new technologies in the form of organ-on-chip, microphysiological systems and 3D bioprinting are all significant emerging areas of the field.
Join us in February 2021, as SMi’s 5th annual 3D Cell Culture Conference brings together industry experts from big pharma, regulatory bodies and the leading biotech companies in the field to discuss the challenges and drivers of the industry, through case studies of the latest innovations in 3D Cell Culture models, real world examples of applications of new technologies and insights into 3D imaging and high throughput screening to give a comprehensive look into this fast growing industry.
source: http://www.smi-online.co.uk/pharmaceuticals/uk/conference/3D-Cell-Culture
If you have any questions about this news, please do not hesitate to contact us.
Join Our Newsletter for Free
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE